Stay updated on PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo
Sign up to get notified when there's something new on the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page.

Latest updates to the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedStudy status changed from Active, not recruiting to Completed; enrollment updated from 120 (Estimated) to 102 (Actual), with related dates adjusted accordingly.SummaryDifference0.4%

- Check20 days agoChange DetectedRevision: v3.3.2 added and v3.2.0 removed from the page's revision history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check27 days agoChange DetectedA government funding-operational notice about potential delays and NIH status was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check42 days agoChange DetectedAdministrative updates were posted on 2025-10-29 and 2025-10-28, including the last update timestamp and QC criteria details. Deletions dated 2025-09-17 and 2025-09-18 indicate routine record maintenance rather than changes to the study design, eligibility, or outcomes.SummaryDifference0.5%

- Check70 days agoChange DetectedAdded a government funding lapse notice and open status for the NIH Clinical Center, plus a new version tag v3.2.0; removed the previous v3.1.0.SummaryDifference3%

- Check78 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo
Enter your email address, and we'll notify you when there's something new on the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page.